A 35-year-old woman with cystic fibrosis is started on tobramycin for chronic Pseudomonas aeruginosa lung infection. The prescriber wants to ensure optimal dosing and minimize nephrotoxicity. Which investigation is most appropriate to monitor for aminoglycoside-induced acute kidney injury?